{"id":115961,"date":"2009-07-16T00:00:00","date_gmt":"2009-07-16T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/report\/fforxx0309-marketaccess-formulary-advantages-in-immune-biologics\/"},"modified":"2009-07-16T00:00:00","modified_gmt":"2009-07-16T00:00:00","slug":"fforxx0309-marketaccess-formulary-advantages-in-immune-biologics","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/fforxx0309-marketaccess-formulary-advantages-in-immune-biologics\/","title":{"rendered":"Formulary Advantages in Immune Biologics: Tightening Payer Control Offers Opportunities for Differentiation"},"content":{"rendered":"<p>Biologics used<br \/>\nto treat immune diseases cost much more than their small-molecule counterparts,<br \/>\nand so their use involves costs disproportionate to the number of patients<br \/>\ntreated. As a result of this disconnect between cost and number of treated<br \/>\npatients, managed care organizations (MCOs) seek to limit the overall use of<br \/>\nimmune biologics. That just four of these biologics (Amgen\/Wyeth\u2019s Enbrel<br \/>\n[etanercept], Centocor Ortho Biotech\u2019s Remicade [infliximab], Roche\u2019s Rituxan<br \/>\n[rituximab] and Abbott\u2019s Humira [adalimumab]) together garner over $9.5 billion<br \/>\nin annual sales in the Unites States alone makes immune biologics a massive<br \/>\ntarget for cost reduction by payers. More than for other groups of drugs,<br \/>\nreimbursement is a key barrier to entry and differentiating feature of immune<br \/>\nbiologics.<\/p>\n<p>Using tiering<br \/>\nand restrictions data from Fingertip Formulary, as well as insight from 40<br \/>\npharmacy directors, this report determines the key trends in reimbursement of<br \/>\nimmune biologics, drivers of these trends, and how stakeholders can capitalize<br \/>\non future shifts in coverage to steal share from the competition.<\/p>\n","protected":false},"template":"","class_list":["post-115961","report","type-report","status-publish","hentry","report-gateway-marketaccess","marketaccess-date-549"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/115961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":0,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/115961\/revisions"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=115961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}